ERBB2 and breast cancer: A previous small study tested an anti-HER2 DC-based vaccine in the adjuvant setting for 7 women with high risk invasive HER2+ (IHC2+ to 3+/FISH+) BC, which had undergone standard treatment (± trastuzumab).